Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Olema Pharmaceuticals Inc (OLMA)

Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Dec 2, 3:30PM CST

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.05 (+4.65%)
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference GlobeNewswire - Fri Nov 21, 3:30PM CST

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.  (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.05 (+4.65%)
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire - Thu Nov 20, 3:01PM CST

SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.05 (+4.65%)
Bullish - green stock market chart with arrow up day trade by Quality Stock Arts via Shutterstock
Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here? Barchart - Wed Nov 19, 10:50AM CST

Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.

OLMA : 33.05 (+4.65%)
RHHBY : 50.0400 (+0.04%)
Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock GlobeNewswire - Wed Nov 19, 6:00AM CST

SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.05 (+4.65%)
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Tue Nov 18, 3:51PM CST

SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.05 (+4.65%)
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results GlobeNewswire - Mon Nov 10, 6:00AM CST

Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancer Initiated OPERA-02 Phase 3 trial of palazestrant...

OLMA : 33.05 (+4.65%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Nov 4, 3:30PM CST

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.05 (+4.65%)
Olema Oncology to Participate in Upcoming Investor Conferences GlobeNewswire - Mon Nov 3, 3:30PM CST

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.  (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.05 (+4.65%)
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 GlobeNewswire - Thu Oct 30, 3:30PM CDT

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.  (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 33.05 (+4.65%)

Barchart Exclusives

Inflation Data, AI Earnings and Other Can't Miss Items this Week Barchart - Sun Dec 14, 12:00PM CST
Markets enter a critical week still reeling from Friday's sharp selloff in technology and AI stocks following disappointing reactions to Oracle and Broadcom earnings that raised questions about AI infrastructure spending sustainability and return on massive capital investments. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot